Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response-Reference-Cited by-同舟云学术

Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response

Published:2017-06 Issue:3 Volume:283 Page:663-672
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Santamaría Gorane¹,Bargalló Xavier¹,Fernández Pedro Luis¹,Farrús Blanca¹,Caparrós Xavier¹,Velasco Martin¹

Affiliation:

1. From the Departments of Radiology (G.S., X.B., M.V.), Pathology (P.L.F.), Radiation Oncology (B.F.), and Gynecology and Obstetrics (X.C.), Hospital Clínic de Barcelona and University of Barcelona Medical School, Villarroel 170, 08036 Barcelona, Spain; and Institut d’Investigacions August Pi i Sunyer, Barcelona, Spain (P.L.F.).

Funder

Ministerio de Economía y Competitividad

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2016160176

Reference32 articles.

1. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis

2. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006

3. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer